Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Increased grip strength with sodium-glucose cotransporter 2.

× No keyword cloud information.

16 in total

1. Empagliflozin reduces blood pressure and uric acid in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.

Authors: Di Zhao; Hui Liu; Pingshuan Dong
Journal: J Hum Hypertens Date: 2018-11-15 Impact factor: 3.012

2. Clinical impact of sarcopenia and dynapenia on diabetes.

Authors: Hiroyasu Mori; Akio Kuroda; Munehide Matsuhisa
Journal: Diabetol Int Date: 2019-06-19

3. Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes.

Authors: Seigo Sugiyama; Hideaki Jinnouchi; Noboru Kurinami; Kunio Hieshima; Akira Yoshida; Katsunori Jinnouchi; Hiroyuki Nishimura; Tomoko Suzuki; Fumio Miyamoto; Keizo Kajiwara; Tomio Jinnouchi
Journal: J Atheroscler Thromb Date: 2017-12-08 Impact factor: 4.928

4. Sodium-glucose cotransporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baseline.

Authors: Kazuyuki Tobe; Hideki Suganami; Kohei Kaku
Journal: J Diabetes Investig Date: 2017-11-13 Impact factor: 4.232

5. Hyperglycemia in non-obese patients with type 2 diabetes is associated with low muscle mass: The Multicenter Study for Clarifying Evidence for Sarcopenia in Patients with Diabetes Mellitus.

Authors: Ken Sugimoto; Yasuharu Tabara; Hiroshi Ikegami; Yasunori Takata; Kei Kamide; Tome Ikezoe; Eri Kiyoshige; Yukako Makutani; Hiroshi Onuma; Yasuyuki Gondo; Kazunori Ikebe; Noriaki Ichihashi; Tadao Tsuboyama; Fumihiko Matsuda; Katsuhiko Kohara; Mai Kabayama; Masahiro Fukuda; Tomohiro Katsuya; Haruhiko Osawa; Yoshihisa Hiromine; Hiromi Rakugi
Journal: J Diabetes Investig Date: 2019-06-01 Impact factor: 4.232

6. Myopathy secondary to empagliflozin therapy in type 2 diabetes.

Authors: Frank Gao; Stephen Hall; Leon A Bach
Journal: Endocrinol Diabetes Metab Case Rep Date: 2020-04-12

7. Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIME-V study).

Authors: Masaya Koshizaka; Ko Ishikawa; Ryoichi Ishibashi; Yoshiro Maezawa; Kenichi Sakamoto; Daigaku Uchida; Susumu Nakamura; Masaya Yamaga; Hidetaka Yokoh; Akina Kobayashi; Shunichiro Onishi; Kazuki Kobayashi; Jun Ogino; Naotake Hashimoto; Hirotake Tokuyama; Fumio Shimada; Emi Ohara; Takahiro Ishikawa; Mayumi Shoji; Shintaro Ide; Kana Ide; Yusuke Baba; Akiko Hattori; Takumi Kitamoto; Takuro Horikoshi; Ryouta Shimofusa; Sho Takahashi; Kengo Nagashima; Yasunori Sato; Minoru Takemoto; L Kristin Newby; Koutaro Yokote
Journal: J Diabetes Investig Date: 2020-08-20 Impact factor: 4.232

8. Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes receiving conventional therapy: clinical implication of the importance of exercise habits during treatment with ipragliflozin.

Authors: Mitsutoshi Kato; Kumiko Sakai; Kyoko Saito; Kensuke Tsutsui; Shigeo Yamashita; Noriko Kato
Journal: Diabetol Int Date: 2017-02-08

9. Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality.

Authors: Taichi Sugizaki; Shunshun Zhu; Ge Guo; Akiko Matsumoto; Jiabin Zhao; Motoyoshi Endo; Haruki Horiguchi; Jun Morinaga; Zhe Tian; Tsuyoshi Kadomatsu; Keishi Miyata; Hiroshi Itoh; Yuichi Oike
Journal: NPJ Aging Mech Dis Date: 2017-09-08

Review 10. The Impact of Antidiabetic Agents on Sarcopenia in Type 2 Diabetes: A Literature Review.

Authors: Chen-Ning Wu; Kai-Jen Tien
Journal: J Diabetes Res Date: 2020-07-09 Impact factor: 4.011